Is lansoprazole (a proton pump inhibitor) safe to use during breastfeeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lansoprazole Use During Breastfeeding

Lansoprazole can be used during breastfeeding, as there is no evidence of harm to the infant, though data are limited and the drug's presence in human milk is unknown. 1

FDA-Approved Labeling Position

The FDA drug label for lansoprazole explicitly states that there is no information regarding the presence of lansoprazole in human milk, the effects on the breastfed infant, or the effects on milk production. 1 However, the label emphasizes that the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for lansoprazole and any potential adverse effects on the breastfed child. 1

Evidence from Related Proton Pump Inhibitors

While direct data on lansoprazole in breast milk are lacking, evidence from omeprazole (a closely related PPI) provides reassuring information:

  • Peak omeprazole concentrations in breast milk were less than 7% of peak serum concentration (58 nM at 3 hours versus 950 nM at 4 hours), indicating minimal secretion into breast milk. 2
  • A breastfeeding mother taking omeprazole 20 mg/day showed no adverse effects in her infant. 2

Clinical Decision-Making Framework

When medications have insufficient data rather than evidence of harm, the standard approach weighs the risk of drug therapy against the risk of untreated maternal symptoms. 3

Key Considerations:

  • Most medications are compatible with breastfeeding, and only a few are absolutely contraindicated (antineoplastics, radiopharmaceuticals, drugs of abuse). 4
  • Women should not be discouraged from breastfeeding while taking compatible medications, given the substantial benefits of breastfeeding for both infant and maternal health. 5
  • Preference should be given to medications with established safety profiles during lactation, particularly those showing minimal transfer to breast milk with a relative infant dose <10% of the maternal dose. 3

Practical Recommendations

If lansoprazole is clinically necessary for the mother:

  • Continue breastfeeding while monitoring the infant for unusual symptoms, including changes in stool pattern, irritability, or poor feeding. 3
  • Consider timing doses immediately after breastfeeding to minimize infant exposure (though this is theoretical given unknown milk levels). 6
  • Use the lowest effective dose for the shortest duration necessary. 4

Important Caveats

  • All medications are excreted into breast milk to some extent, with the amount depending on drug characteristics, maternal pharmacokinetics, and dosing. 6
  • Clear, safe, and reliable information is still lacking for most drugs during lactation, including lansoprazole specifically. 7
  • The decision should involve shared decision-making between clinician and patient, balancing maternal therapeutic need against theoretical infant risk. 1, 4

References

Research

Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation.

Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 1998

Guideline

Serrapeptase Use During Breastfeeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Breastfeeding and maternal medications].

Jornal de pediatria, 2004

Guideline

Mucinex Safety During Breastfeeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Drugs in lactation.

The journal of obstetrics and gynaecology research, 2019

Research

Drugs and breastfeeding: instructions for use.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.